猪胰岛素前体在酵母Kluyveromyces lactis中的分泌…

通过对包括猪胰岛素前体（ＰＩＰ）基因在内的表达框架克隆至质粒ｐＫＤ１衍生的两种载体上而在酵母Ｋｌｕｙｖｅｒｏｍｙｃｅｓ ｌａｃｔｉｓ中分泌表达猪胰岛素前体。根据放射免疫测定结果,猪胰岛素前体的表达水平为２０－３０ｍｇ／Ｌ,猪胰素胶体经过胰肽被转变基因工程人胰岛素,分析结果表明,来自Ｋ．ｌａｃｔｉｓ的人胰岛素,其氨基酸组成、晶体形状和生物活力天然胰岛素相同。     

B8Gly在胰岛素结构模体中的可能作用

在胰岛素结构模体ｎ１－Ｃｙｓ－Ｇｌｙ－Ｘ１０－Ｃｙｓ－ｎ２－Ｃｙｓ－Ｃｙｓ－Ｘ３－Ｃｙｓ－Ｘ８－Ｃｙｓ－ｎ３中,有７个绝对保守的氨基酸残基,只有位于Ｂ８位的是Ｇｌｙ。通过定点突变将其改变为Ａｌａ,得到「Ｂ８Ａｌａ」人胰岛素,其受体结合能力和体内生物活力分别为天然猪胰岛素的２．５％和１０％。「Ｂ８Ａｌａ」人胰岛素和重组人胰岛素的远紫外圆二色谱比较表明,「Ｂ８Ａｌａ」人胰岛素的α－螺旋的相对含量有一家     

胰岛素蛋白质工程：高活性（B10Asp）人胰岛素

用基因定位突变方法将胰岛素Ｂ链第１０位的Ｈｉｓ变为Ａｓｐ,获得高活力胰岛素（Ｂ１０Ａｓｐ）人胰岛素,其受体结合能力和离体生物少分别为猪胰岛素的２６２％和２３５％体内生物活力也明显高于猪胰岛素,它的促细胞生长能力为猪胰岛素的１７４％。     

Met-Lys-双C肽人胰岛素原基因的构建表达及分离纯化

应用 Ｐ Ｃ Ｒ 定点突变方法构建编码 Ｍ ｅｔ Ｌｙｓ 双 Ｃ 肽人胰岛素原基因,并在大肠杆菌中以包含体方式获得表达 表达产物经还原、重组、 Ｓｅｐｈａｄｅｘ Ｇ ７５ 分离纯化,获得 Ｍ ｅｔ Ｌｙｓ 双 Ｃ 肽人胰岛素原,经胰蛋白酶与羧肽酶 Ｂ的酶解, Ｒｅｓｏｕｒｃｅ Ｔ Ｍ Ｑ 阴离子交换柱层析分离制备得人胰岛素,其放免活性、受体结合活性均与猪胰岛素相同      

一种重组抗胰蛋白酶单体人胰岛素突变体的设计,制备？…

用缺口双链ＤＮＡ的定向突变方法分别将胰岛素前体中Ｂ链第２２、２８、２９和３０位改变为Ａｓｐ、Ｌｙｓ、Ｐｒｏ和Ｌｙｓ,酵母分泌表达的前体经胰蛋白酶直接酶切,得到重组〔Ｂ２２Ａｓｐ、Ｂ２８Ｌｙｓ、Ｂ２９Ｐｒｏ、Ｂ３０Ｌｙｓ〕人胰岛素。它与受体的结合能力约为猪胰岛素的６％,而体内生物活力保留５０％。通过ＦＰＬＣ分子筛测定其自身结合能力,在生理条件下浓度达１０＾－４ｍｏｌ／Ｌ时它以单体形式存在。作为可抗胰     

胰岛素蛋白质工程：高活性［B10Asp］人胰岛素

用基因定位突变方法将胰岛素Ｂ链第１０位的Ｈｉｓ变为Ａｓｐ,获得高活力胰岛素──［Ｂ１０Ａｓｐ］人胰岛素。其受体结合能力和离体生物活力分别为猪胰岛素的２６２％和２３５％;体内生物活力也明显高于猪胰岛素;它的促细胞生长能力为猪胰岛素的１７４％。     

乳酸克鲁维酵母高拷贝整合载体的构建及应用

用酿酒酵母２６ｓ ｒＤＮＡ作探针克隆乳酸克鲁维酵母Ｋ．ｌａｃｔｉｓ ２．２ｋｂ ｒＤＮＡ片段,对其作限制内切酶图谱分析。以该基因片段为同源整合的靶顺序,酿酒酵 ＵＲＡ３基因为选择标记构载体质粒ｐＩＲＫ并对其在宿主Ｋ．ｌａｃｔｉｓ ＭＷ９８－８ｃ细胞中的整合位点,拷数及稳定性进行测定和分析。     

B22Asn人胰岛素突变体的研究

通过ＤＮＡ定点突变法将人胰岛素Ｂ２２Ａｒｇ改造成Ｂ２２Ａｓｎ,去除其一级结构中碱性蛋白酶位点,以期提高胰岛素在体内的稳定性,突变体基因克隆到表达载体ＰＢＶ２２０中,在Ｅ．ｃｏｌｉ ＤＨ５α中进行表达,分离纯化后的表达产物经胰蛋白酶和羧肽酶Ｂ联合作用获得重组Ｂ２２Ａｓｎ－人胰岛素,该突变胰岛素具有抗胰蛋白酶水解能力,但是其与受体的结合能力只有标准猪胰岛素的１２．４％,胰岛素结构中的Ｂ２２Ａｒｇ可能在     

人胰岛素在甲醇酵母Pichia pastoris中的分泌表达

将猪胰岛素前体基因和在其５’端引入９个氨基酸的间隔肽序列的ＰＩＰ基因插入到Ｐｉｃｈｉａ ｐａｓｔｏｒｉｓ的分泌表达质粒ｐＰＩＣ９中,得到分泌表达质粒ｐｐＩＣ９／ＰＩＰ和ｐＰＣ９／ｓｐ－ＰＩＰ７并用以转化ｐａｓｔｏｒｉｓ ＧＳ１１５。用点杂交筛选,获得高拷贝转化Ｐ３９（－ｓｐ）和Ｓ５１（＋ｓｐ）。     

双链杂交分子“胰岛素—类胰岛素生长因子—I”

以去Ｂ链Ｃ端八肽胰岛素和化学合成的ＩＧＦ－Ｉ的２２－２９及２２－３２为底物,用酶促半合成方法制备了杂交分子“胰岛素－类胰岛素茵子－Ｉ”,Ｉｎｓ／ＩＧＦ－Ｉ和Ｉｎｓ－ＩＧＦ－Ｉ。研究了它们的胰岛中生物活性。结果表明,猪胰岛素Ｂ链Ｃ端Ｂ２７的Ｔｈｒ被Ａｓｎ取代,Ｂ３０的Ａｌａ被Ａｌａ被Ｔｈｒ取代同时Ｂ２５－Ｂ２６及Ｂ２８－Ｂ２９氨基酸顺序颠紧及在Ｂ链Ｃ末端延长３肽都不影响胰岛素的生物活力。     

Regulation of Insulin Secretion by Phosphatidylinositol-4,5-Bisphosphate

The role of PIP₂ in pancreatic beta cell function was examined here using the beta cell line MIN6B1. Blocking PIP₂ with PH-PLC-GFP or PIP5KIγ RNAi did not impact on glucose-stimulated secretion although susceptibility to apoptosis was increased. Over-expression of PIP5KIγ improved cell survival and inhibited secretion with accumulation of endocytic vacuoles containing F-actin, PIP₂, transferrin receptor, caveolin 1, Arf6 and the insulin granule membrane protein phogrin but not insulin. Expression of constitutively active Arf6 Q67L also resulted in vacuole formation and inhibition of secretion, which was reversed by PH-PLC-GFP co-expression. PIP₂ co-localized with gelsolin and F-actin, and gelsolin co-expression partially reversed the secretory defect of PIP5KIγ-over-expressing cells. RhoA/ROCK inhibition increased actin depolymerization and secretion, which was prevented by over-expressing PIP5KIγ, while blocking PIP₂ reduced constitutively active RhoA V14-induced F-actin polymerization. In conclusion, although PIP₂ plays a pro-survival role in MIN6B1 cells, excessive PIP₂ production because of PIP5KIγ over-expression inhibits secretion because of both a defective Arf6/PIP5KIγ-dependent endocytic recycling of secretory membrane and secretory membrane components such as phogrin and the RhoA/ROCK/PIP5KIγ-dependent perturbation of F-actin cytoskeleton remodelling.     

Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin

Blood glucose lowering assay proved that [B16Ala]insulin and [B26Ala]insulin exhibit potency of acute blood glucose lowering in normal pigs, which demonstrates that they are fast- acting insulin. Single-chain precursor of [B16Ala]insulin and [B26Ala]insulin is [B16Ala]PIP and [B26Ala]PIP, respectively, which are suitable for gene expression. Secretory expression level of the precursors in methylotrophic yeast Pichia pastoris was quite high, 650 mg/L and 130 mg/L, respectively. In vivo biological assay showed that the two fast-acting insulins have full or nearly full biological activity. So both [B16Ala]insulin and [B26Ala]insulin can be well developed as fast-acting insulin for clinic use.     

Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin

Insulin has been successfully used in clinic treatment of diabetes for more than 80 years. However, the clinic practice has shown that regular insulin preparation used in clinic exhibits several intrinsic problems that have existed for a long time. One of the major problems is that insulin has a potency of self-association when its concentration is higher than physiological concentration (10-8—10-10 mol/L)[1,2]. The concentration of the regular insulin is higher than 10-4 mol/L. At such a hi…     

牛胰岛素的酰胺化反应及其六酰胺产物的分离及鉴定

牛胰岛素用1％三氟化硼甲醇溶液反应后所得六甲酯与饱和氨甲醇溶液反应,在室温下约经144小时可完全酰胺化。反应过程用红外光谱及酰胺含量分析测定。所得酰胺化粗产品经Sephadex G-75凝胶层析可以将胰岛素六酰胺化合物从其聚合物中分离提纯。由红外光谱、紫外光谱及圆二色散光谱测定表明:牛胰岛素的六酰胺化合物的构象与胰岛素有很大不同,其生物活性也丧失殆尽。     

The relationship between the connecting peptide of recombined single chain insulin and its biological function

To investigate the relationship between the biological activity of recombined single chain insulin and the length of the connecting peptide, we designed and prepared three single chain insulin molecules, namely, PIP, [A]5PIP and [A]10PIP, by site-directed mutagenesis, in which B30 and A1 were linked through dipeptide A-K, heptapeptide A-A-A-A-A-A-K, and dodecapeptide A-A-A-A-A-A-A-A-A-A-A-K, respectively. Their receptor binding capacities were 0.14%, 14.3% and 11.1% of that of insulin respectively and their in vivo biological activities were in consistence with their receptor binding capacity; whereas their growth promoting activities were 17%, 116.3% and 38% of that of insulin. These results suggested the following conclusions. (i) The recombined single chain insulin could also possess the same metabolic and mitogenic function as insulin. (ii) The receptor binding capacity of recombined single chain insulin to insulin receptor was closely related to the length and amino acid composition of the connectin     

The relationship between the connecting peptide of recombined single chain insulin and its biological function

To investigate the relationship between the biological activity of recombined single chain insulin and the length of the connecting peptide, we designed and prepared three single chain insulin molecules, namely, PIP, [A]₅PIP and [A]₁₀PIP, by site-directed mutagenesis, in which B30 and A1 were linked through dipeptide A-K, heptapeptide A-A-A-A-A-A-K, and dodecapeptide A-A-A-A-A-A-A-A-A-A-A-K, respectively. Their receptor binding capacities were 0.14%, 14.3% and 11.1% of that of insulin respectively and theirin vivo biological activities were in consistence with their receptor binding capacity; whereas their growth promoting activities were 17%, 116.3% and 38% of that of insulin. These results suggested the following conclusions. (i) The recombined single chain insulin could also possess the same metabolic and mitogenic function as insulin. (ii) The receptor binding capacity of recombined single chain insulin to insulin receptor was closely related to the length and amino acid composition of the connecting peptide and could change from 0 to 100% of insulin depending on the different connecting peptides. This result further illustrated the necessity of B chain C-terminus swaying away from A chain N-terminus when insulin binds to its receptor. (iii) The mitogenic activity of recombined single chain insulin also depended on the length and the amino acid composition of the connecting peptide and was higher than its metabolic activity.     

Endothelin-1 impairs glucose transporter trafficking via a membrane-based mechanism

Endothelin-1 (ET-1) disrupts insulin-regulated glucose transporter GLUT4 trafficking. Since the negative consequence of chronic ET-1 exposure appears to be independent of signal disturbance along the insulin receptor substrate-1/phosphatidylinositol (PI) 3-kinase (PI3K)/Akt-2 pathway of insulin action, we tested if ET-1 altered GLUT4 regulation engaged by osmotic shock, a PI3K-independent stimulus that mimics insulin action. Regulation of GLUT4 by hyperosmotic stress was impaired by ET-1. Because of the mutual disruption of both insulin- and hyperosmolarity-stimulated GLUT4 translocation, we tested whether shared signaling and/or key phosphatidylinositol 4,5-bisphosphate (PIP2)-regulated cytoskeletal events of GLUT4 trafficking were targets of ET-1. Both insulin and hyperosmotic stress signaling to Cbl were impaired by ET-1. Also, plasma membrane PIP2 and cortical actin levels were reduced in cells exposed to ET-1. Exogenous PIP2, but not PI 3,4,5-bisphosphate, restored actin structure, Cbl activation, and GLUT4 translocation. These data show that ET-1-induced PIP2/actin disruption impairs GLUT4 trafficking elicited by insulin and hyperosmolarity. In addition to showing for the first time the important role of PIP2-regulated cytoskeletal events in GLUT4 regulation by stimuli other than insulin, these studies reveal a novel function of PIP2/actin structure in signal transduction.     

Insulin Reverses Enhanced Incorporation of 32P into Polyphosphoinositides in Peripheral Nerve of the Streptozotocin Diabetic Rat

The ability of insulin treatment to reverse altered phosphoinositide metabolism in sciatic nerve from streptozotocin diabetic rats was studied. Diabetes was induced in rats by means of a single injection of streptozotocin. Enhanced incorporation of 32P into phosphatidylinositol-4,5-bisphosphate (PIP2) was detectable as early as 8 days following intravenous injection of streptozotocin and was maximal after 4 weeks. Hormone treatment was initiated at this time by daily injections of protamine zinc insulin followed by the implantation of long-acting insulin osmotic minipumps, and 4 weeks later sciatic nerves were removed and incubated in the presence of [32P]orthophosphate. The increased labeling of PIP2 was completely reversed by hormone administration. In contrast, insulin (0.1 and 1.0 mU/ml) added to the incubation medium failed to reverse the altered pattern of 32P incorporation into PIP2. The uptake of 32P into PIP2 was greater than 80% higher into the proximal than into the distal portion of normal sciatic nerve when these were incubated separately. This metabolic difference was abolished in diabetic rats, although the incorporation into both segments was still significantly higher than in controls. These results strengthen the association of altered nerve PIP2 metabolism with the diabetic state and are consistent with the concept that experimental diabetic neuropathy is a distal axonopathy.     

Insulin receptor internalization and signalling

The insulin receptor kinase (IRK) is a tyrosine kinase whose activation, subsequent to insulin binding, is essential for insulin-signalling in target tissues. Insulin binding to its cell surface receptor is rapidly followed by internalization of insulin-IRK complexes into the endosomal apparatus (EN) of the cell. Internalization of insulin into target organs, especially liver, is implicated in effecting insulin clearance from the circulation. Internalization mediates IRK downregulation and hence attenuation of insulin sensitivity although most internalized IRKs readily recycle to the plasma membrane at physiological levels of insulin. A role for internalization in insulin signalling is indicated by the accumulation of activated IRKs in ENs. Furthermore, the maximal level of IRK activation has been shown to exceed that attained at the cell surface. Using an in vivo rat liver model in which endosomal IRKs are exclusively activated has revealed that IRKs at this intracellular locus are able by themselves to promote IRS-1 tyrosine phosphorylation and induce hypoglycemia. Furthermore, studies with isolated rat adipocytes reveal the EN to be the principle site of insulin-stimulated IRS-1 tyrosine phosphorylation and associated PI3K activation. Key steps in the termination of the insulin signal are also operative in ENs. Thus, an endosomal acidic insulinase has been identified which limits the extent of IRK activation. Furthermore, IRK dephosphorylation is effected in ENs by an intimately associated phosphotyrosine phosphatase(s) which, in rat liver, appears to regulate IRK activity in both a positive and negative fashion. Thus, insulin-mediated internalization of IRKs into ENs plays a crucial role in effecting and regulating signal transduction in addition to modulating the levels of circulating insulin and the cellular concentration of IRK in target tissues.